IRCT20240804062647N1
Recruiting
未知
Bioequivalence study of famotidine 40 mg tablets produced by Actoverco pharmaceutical company with the reference drug Pepcid 40 mg manufactured by Merck company
?Actoverco Pharmaceutical Company0 sites24 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- This study is performed on healthy volunteers and drug concentration in plasma is determined..
- Sponsor
- ?Actoverco Pharmaceutical Company
- Enrollment
- 24
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18\-30\)
- •Informed consent
- •Age (18\-55 years old)
Exclusion Criteria
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcoholism and Narcoticism
- •History of allergy to Famotidine
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Bioequivalence study of famotidine 40 mg tabletIRCT20230222057495N12Ramopharmin Pharmaceutical Company24
Completed
Not Applicable
Bioequivalance study of Famotidine 40 mgIRCT20200513047423N5Fatak chemie pars Pharmacy24
Not yet recruiting
Not Applicable
Bioequivalance study of Famotidine 40 mgSubject: Bioequivalence of Famotidine 40 mg Tablet and Comparison of Pharmacokinetic Parameters with Ratiopham Reference Tablet.IRCT20200513047423N9Iran Daru Pharmaceutical Company24
Recruiting
Not Applicable
Bioequivalence study of Famotidine 40 mg tabletIRCT20210519051345N32Tabriz University of Medical Sciences24
Not yet recruiting
Not Applicable
Bioequivalence study of Famotidine 40 mgIRCT20200623047902N14Sanamed pharma company24